Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brigatinib

FDA-approved product (tablet, oral), marketed as Alunbrig.

Registered studies
48
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Brigatinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm
  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anaplastic lymphoma kinase (alk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli51.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

48registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brigatinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brigatinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer

    NCT07771764 · start 2026-08-01

    Registered record
    Registry ID
    NCT07771764
    Conditions
    ALK-positive Non Small Cell Lung Cancer
    Interventions
    iruplaltinib and pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionALK-positive Non Small Cell Lung Cancer
    Interventioniruplaltinib and pemetrexed
    PhasePhase 2
    Registry statusNot yet recruiting

  • OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy

    NCT07655583 · start 2026-05-27

    Registered record
    Registry ID
    NCT07655583
    Conditions
    Brain Metastasis; Stereotactic Radiosurgery; Resection; Systemic Therapy
    Interventions
    Systemic therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-05-27
    Completion
    2030-06-30
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Metastasis; Stereotactic Radiosurgery; Resection; Systemic Therapy
    InterventionSystemic therapy
    PhasePhase 1
    Registry statusRecruiting

  • Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

    NCT06620835 · start 2025-06-19

    Registered record
    Registry ID
    NCT06620835
    Conditions
    NSCLC
    Interventions
    Blood samples for Hematology; Blood samples for Chemistry; Blood sample for liver function tests; Pregnancy test; Tumour assessment; Local Ablative Therapy (LAT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-19
    Completion
    2030-10-01
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC
    InterventionBlood samples for Hematology; Blood samples for Chemistry; Blood sample for liver function tests; Pregnancy test +2 more
    PhasePhase 2
    Registry statusRecruiting

  • Using Tumor Models to Determine Treatments

    NCT06813079 · start 2025-04-07

    Registered record
    Registry ID
    NCT06813079
    Conditions
    Pancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor
    Interventions
    Cobimetinib; Ponatinib; Brigatinib; Colchicine; Selinexor; Abemaciclib; Neratinib; Doxorubicin; Etoposide; Ceritinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-04-07
    Completion
    2028-02-17
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Ductal Carcinoma; Advanced Cancer; Epithelial Tumor
    InterventionCobimetinib; Ponatinib; Brigatinib; Colchicine +6 more
    PhasePhase 2
    Registry statusRecruiting

  • Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

    NCT06522360 · start 2024-12-11

    Registered record
    Registry ID
    NCT06522360
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Brigatinib; Carboplatin; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-12-11
    Completion
    2025-04-17
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionBrigatinib; Carboplatin; Pemetrexed
    PhasePhase 2
    Registry statusWithdrawn

  • ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

    NCT06532149 · start 2024-08-05

    Registered record
    Registry ID
    NCT06532149
    Conditions
    NSCLC Stage IV; Sex Disorder; Hypogonadism, Male; Erectile Dysfunction
    Interventions
    Alectinib; Brigatinib; Lorlatinib 100 mg; Osimertinib; Sotorasib; Dabrafenib; Trametinib; Selpercatinib; Pembrolizumab; Cemiplimab; Nivolumab; Carboplatin; Pemetrexed; Paclitaxel
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2024-08-05
    Completion
    2026-09-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC Stage IV; Sex Disorder; Hypogonadism, Male; Erectile Dysfunction
    InterventionAlectinib; Brigatinib; Lorlatinib 100 mg; Osimertinib +10 more
    PhaseNot recorded
    Registry statusRecruiting

  • Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

    NCT05718297 · start 2024-06-07

    Registered record
    Registry ID
    NCT05718297
    Conditions
    NSCLC, Stage III; ALK-rearrangement
    Interventions
    Brigatinib; Durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-06-07
    Completion
    2024-09-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC, Stage III; ALK-rearrangement
    InterventionBrigatinib; Durvalumab
    PhasePhase 2
    Registry statusWithdrawn

  • A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)

    NCT05721950 · start 2024-01-17

    Registered record
    Registry ID
    NCT05721950
    Conditions
    Non-small Cell Lung Cancer (NSCLC)
    Interventions
    Brigatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2024-01-17
    Completion
    2028-12-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer (NSCLC)
    InterventionBrigatinib
    PhaseNot recorded
    Registry statusActive not recruiting

  • A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

    NCT06132867 · start 2023-12-20

    Registered record
    Registry ID
    NCT06132867
    Conditions
    Healthy Volunteers
    Interventions
    Brigatinib; Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-12-20
    Completion
    2024-02-17
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionBrigatinib; Brigatinib
    PhasePhase 1
    Registry statusCompleted

  • A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

    NCT05834348 · start 2023-06-23

    Registered record
    Registry ID
    NCT05834348
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    lorlatinib; crizotinib; brigatinib; ceritinib; alectinib; atezolizumab; bevacizumab; paclitaxel; carboplatin; docetaxel; erlotinib; gefitinib; afatinib; dacomitinib; osimertinib; pembrolizumab; nivolumab; entrectinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-06-23
    Completion
    2024-01-23
    Enrolment
    5,279

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    Interventionlorlatinib; crizotinib; brigatinib; ceritinib +14 more
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY

    NCT05735327 · start 2023-05-22

    Registered record
    Registry ID
    NCT05735327
    Conditions
    Non-small Cell Lung Cancer (NSCLC)
    Interventions
    No intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2023-05-22
    Completion
    2027-04-26
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer (NSCLC)
    InterventionNo intervention
    PhaseNot recorded
    Registry statusActive not recruiting

  • Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

    NCT04925609 · start 2022-08-18

    Registered record
    Registry ID
    NCT04925609
    Conditions
    Anaplastic Large Cell Lymphoma, ALK-Positive; Inflammatory Myofibroblastic Tumor; Other Solid Tumor
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2022-08-18
    Completion
    2033-12
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnaplastic Large Cell Lymphoma, ALK-Positive; Inflammatory Myofibroblastic Tumor; Other Solid Tumor
    InterventionBrigatinib
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    NCT05384626 · start 2022-06-09

    Registered record
    Registry ID
    NCT05384626
    Conditions
    Locally Advanced Solid Tumor; Metastatic Solid Tumor
    Interventions
    Neladalkib (NVL-655); Midazolam; Repaglinide; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2022-06-09
    Completion
    2028-01
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLocally Advanced Solid Tumor; Metastatic Solid Tumor
    InterventionNeladalkib (NVL-655); Midazolam; Repaglinide; Itraconazole
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

    NCT05361564 · start 2022-06

    Registered record
    Registry ID
    NCT05361564
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Brigatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-06
    Completion
    2024-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionBrigatinib
    PhasePhase 2
    Registry statusUnknown

  • Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

    NCT05200481 · start 2022-05-18

    Registered record
    Registry ID
    NCT05200481
    Conditions
    Non Small Cell Lung Cancer; ALK Gene Mutation
    Interventions
    Brigatinib 180 MG; Carboplatin; Pemetrexed
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2022-05-18
    Completion
    2028-10
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer; ALK Gene Mutation
    InterventionBrigatinib 180 MG; Carboplatin; Pemetrexed
    PhasePhase 2
    Registry statusActive not recruiting